<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538654</url>
  </required_header>
  <id_info>
    <org_study_id>EMF2011</org_study_id>
    <nct_id>NCT01538654</nct_id>
  </id_info>
  <brief_title>Enteroprotein Modified Fast ( EMF )</brief_title>
  <acronym>EMF</acronym>
  <official_title>Enteroprotein Modified Fast ( EMF ) : Clinical Safety and Efficacy. A Six Months Pilot RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Samir G. Sukkar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestl√© Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the esperience is:&#xD;
&#xD;
        1. to verify the safety of protein sparing modified fast(PSMF) by enteral route ( EMF&#xD;
           )performed in cycles of ten days/months for six months&#xD;
&#xD;
        2. to compare EMF with oral PSMF clinically ( appetite control, fat freemass mantainance,&#xD;
           polmonary function tests and metabolic pattern)&#xD;
&#xD;
        3. to verify the weight mantainance after 6 months from the treatment suspension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale A) primary endpoint&#xD;
&#xD;
        1. to verify the safety of protein sparing modified fast by enteral route ( EMF )in cycles&#xD;
           of ten days/months repeated for six months,&#xD;
&#xD;
        2. To compare EMF with oral PSMF clinically ( appetite control, polmonary function tests&#xD;
           and metabolic pattern) and on metabolic parameters (hypertension, glucose intolerance,&#xD;
           dyslipidaemia) maintaining body composition (particularly fat free mass and muscular&#xD;
           strength) in 15 patients with disease-causing obesity not responding to medical&#xD;
           treatment and/or cognitive/behavioural therapy, who are candidates for invasive&#xD;
           treatment such as the gastric balloon or surgery but do not intend to undergo them&#xD;
           compared with 15 undergoing the same regimen without the naso-gastric tube. To verify&#xD;
           the effects of treatment with regard to the enteral-hormonal structure during the acute&#xD;
           phase (selected sub-group) and while undergoing treatment.&#xD;
&#xD;
      B) Secondary endpoints:&#xD;
&#xD;
        1. To verify the percentage of patients who maintain the weight reached 6 months after&#xD;
           stopping treatment with the naso-gastric tube associated with a high-calorie&#xD;
           normal-protein diet.&#xD;
&#xD;
        2. Verify clinical safety of EN in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2011</start_date>
  <completion_date type="Actual">December 20, 2012</completion_date>
  <primary_completion_date type="Actual">December 20, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PSMF by tube feeding side effects</measure>
    <time_frame>at the day 10th /month for 6 months</time_frame>
    <description>Evaluation of side effects due to enteral nutrition by tube with a PSMF in obese subjects</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>'enteral protein tube feeding in obese</arm_group_label>
    <description>protein sparing modified fast with a defined enteral formula by tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enteral protein tube feeding in obese</intervention_name>
    <description>The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding</description>
    <arm_group_label>'enteral protein tube feeding in obese</arm_group_label>
    <other_name>EMF ( enteral modified fast )</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with BMI 30 - 45 Kg/m2&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  both genders, outpatients&#xD;
&#xD;
          -  aged between 16 and 75&#xD;
&#xD;
          -  with BMI 30 - 45 Kg/m2&#xD;
&#xD;
          -  that are not in a restricted diet since at least 3 months&#xD;
&#xD;
          -  with obesity related comorbidities (- type 2 diabetes&#xD;
&#xD;
          -  mild or moderate OSAS&#xD;
&#xD;
          -  orthopedic diseases (coxarthrosis, gonarthrosis)&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  non alcoholic hepatic steatosis&#xD;
&#xD;
          -  accepting to be enrolled in the study (signing informed consent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of gastrointestinal diseases&#xD;
&#xD;
          -  Presence of cancer&#xD;
&#xD;
          -  Patients treated with gastrolesive or anticoagulant drugs&#xD;
&#xD;
          -  Hepatic failure, renal failure or multi-organ failure (cut off)&#xD;
&#xD;
          -  Contraindications for enteral nutrition,Mechanical bowel complete, or partial chronic&#xD;
             obstruction&#xD;
&#xD;
          -  Severe mesenteric ischemia not caused by hypovolemia&#xD;
&#xD;
          -  Digiunal or ileal fistula with high output (400 mL/die)&#xD;
&#xD;
          -  Severe modifications of the intestinal function caused by enteropathies or&#xD;
             insufficient absorbent surface, to the point that a normal nutritional state cannot be&#xD;
             maintained&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Type 2 diabetes treated with oral or injected drugs that may cause hypoglycemia&#xD;
&#xD;
          -  ANBN: anorexia or bulimia nervosa, evaluation of other symptoms by specific tests&#xD;
&#xD;
          -  Patients with major psychiatric disorders or not cooperative, or with alcohol or drug&#xD;
             addiction disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir G Sukkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>M.D. Samir G. Sukkar</investigator_full_name>
    <investigator_title>Chief Clinical Nutrition Unit</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>PSMF ( protein sparing modified fast)</keyword>
  <keyword>Enteral nutrition</keyword>
  <keyword>Tube feeding</keyword>
  <keyword>VLCD ( very low calorie diet)</keyword>
  <keyword>Pulmonary function tests</keyword>
  <keyword>body composition</keyword>
  <keyword>FFM ( fat free mass)</keyword>
  <keyword>Body fat</keyword>
  <keyword>Handgripstregth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

